Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts

Concurrent tumourigenesis

G. Hortelano, L. Wang, N. Xu, F. A. Ofosu

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

This study reports the generation of an immunodeficient murine model for haemophilia B, obtained by breeding factor IX-deficient mice with an immunodeficient mouse strain, and use of this mouse model to evaluate the long-term efficacy and safety of a gene therapy strategy for treating haemophilia B. Nude haemophilic mice were implanted with biocompatible microcapsules enclosing recombinant myoblasts secreting human factor IX. The activated partial thromboplastin time (APTT) of plasma of mice thus treated was invariably shortened 3 weeks after microcapsule implantation, and remained shortened for at least 77 days. Shortening of the APTT of the haemophilia mice coincided with the appearance of human factor IX in mice plasmas (up to 600 ng mL-1 on day 77), and normalization of the tail-bleeding time. Thus, the microencapsulated myoblasts reversed the clinical phenotype of haemophilia B. In contrast, plasmas of immunocompetent haemophilic mice similarly implanted with microcapsules only showed a transient shortening of APTT, and coincident transient delivery of human factor IX antigen. Rapid disappearance of human factor IX from plasmas of immunocompetent mice also coincided with production of antibodies to the human transgene. Significantly, 86% of the nude haemophilia mice developed tumours of myoblast origin. Thus, while this study revealed the feasibility of this gene therapy approach to treat severe haemophilia B, it also highlights the importance of using safer cell lines to prevent tumour development.

Original languageEnglish
Pages (from-to)207-214
Number of pages8
JournalHaemophilia
Volume7
Issue number2
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Hemophilia B
Factor IX
Myoblasts
Partial Thromboplastin Time
Capsules
Hemophilia A
Therapeutics
Nude Mice
Genetic Therapy
Bleeding Time
Feasibility Studies
Transgenes
Antibody Formation
Breeding
Tail
Neoplasms
Phenotype
Safety
Antigens
Cell Line

Keywords

  • C2C12 myoblast
  • Factor IX
  • Gene therapy
  • Haemophilia B
  • Microcapsules

ASJC Scopus subject areas

  • Hematology

Cite this

Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts : Concurrent tumourigenesis. / Hortelano, G.; Wang, L.; Xu, N.; Ofosu, F. A.

In: Haemophilia, Vol. 7, No. 2, 2001, p. 207-214.

Research output: Contribution to journalArticle

@article{08151c11a794499e857ae23c2df906cc,
title = "Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: Concurrent tumourigenesis",
abstract = "This study reports the generation of an immunodeficient murine model for haemophilia B, obtained by breeding factor IX-deficient mice with an immunodeficient mouse strain, and use of this mouse model to evaluate the long-term efficacy and safety of a gene therapy strategy for treating haemophilia B. Nude haemophilic mice were implanted with biocompatible microcapsules enclosing recombinant myoblasts secreting human factor IX. The activated partial thromboplastin time (APTT) of plasma of mice thus treated was invariably shortened 3 weeks after microcapsule implantation, and remained shortened for at least 77 days. Shortening of the APTT of the haemophilia mice coincided with the appearance of human factor IX in mice plasmas (up to 600 ng mL-1 on day 77), and normalization of the tail-bleeding time. Thus, the microencapsulated myoblasts reversed the clinical phenotype of haemophilia B. In contrast, plasmas of immunocompetent haemophilic mice similarly implanted with microcapsules only showed a transient shortening of APTT, and coincident transient delivery of human factor IX antigen. Rapid disappearance of human factor IX from plasmas of immunocompetent mice also coincided with production of antibodies to the human transgene. Significantly, 86{\%} of the nude haemophilia mice developed tumours of myoblast origin. Thus, while this study revealed the feasibility of this gene therapy approach to treat severe haemophilia B, it also highlights the importance of using safer cell lines to prevent tumour development.",
keywords = "C2C12 myoblast, Factor IX, Gene therapy, Haemophilia B, Microcapsules",
author = "G. Hortelano and L. Wang and N. Xu and Ofosu, {F. A.}",
year = "2001",
doi = "10.1046/j.1365-2516.2001.00492.x",
language = "English",
volume = "7",
pages = "207--214",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley Blackwell",
number = "2",

}

TY - JOUR

T1 - Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts

T2 - Concurrent tumourigenesis

AU - Hortelano, G.

AU - Wang, L.

AU - Xu, N.

AU - Ofosu, F. A.

PY - 2001

Y1 - 2001

N2 - This study reports the generation of an immunodeficient murine model for haemophilia B, obtained by breeding factor IX-deficient mice with an immunodeficient mouse strain, and use of this mouse model to evaluate the long-term efficacy and safety of a gene therapy strategy for treating haemophilia B. Nude haemophilic mice were implanted with biocompatible microcapsules enclosing recombinant myoblasts secreting human factor IX. The activated partial thromboplastin time (APTT) of plasma of mice thus treated was invariably shortened 3 weeks after microcapsule implantation, and remained shortened for at least 77 days. Shortening of the APTT of the haemophilia mice coincided with the appearance of human factor IX in mice plasmas (up to 600 ng mL-1 on day 77), and normalization of the tail-bleeding time. Thus, the microencapsulated myoblasts reversed the clinical phenotype of haemophilia B. In contrast, plasmas of immunocompetent haemophilic mice similarly implanted with microcapsules only showed a transient shortening of APTT, and coincident transient delivery of human factor IX antigen. Rapid disappearance of human factor IX from plasmas of immunocompetent mice also coincided with production of antibodies to the human transgene. Significantly, 86% of the nude haemophilia mice developed tumours of myoblast origin. Thus, while this study revealed the feasibility of this gene therapy approach to treat severe haemophilia B, it also highlights the importance of using safer cell lines to prevent tumour development.

AB - This study reports the generation of an immunodeficient murine model for haemophilia B, obtained by breeding factor IX-deficient mice with an immunodeficient mouse strain, and use of this mouse model to evaluate the long-term efficacy and safety of a gene therapy strategy for treating haemophilia B. Nude haemophilic mice were implanted with biocompatible microcapsules enclosing recombinant myoblasts secreting human factor IX. The activated partial thromboplastin time (APTT) of plasma of mice thus treated was invariably shortened 3 weeks after microcapsule implantation, and remained shortened for at least 77 days. Shortening of the APTT of the haemophilia mice coincided with the appearance of human factor IX in mice plasmas (up to 600 ng mL-1 on day 77), and normalization of the tail-bleeding time. Thus, the microencapsulated myoblasts reversed the clinical phenotype of haemophilia B. In contrast, plasmas of immunocompetent haemophilic mice similarly implanted with microcapsules only showed a transient shortening of APTT, and coincident transient delivery of human factor IX antigen. Rapid disappearance of human factor IX from plasmas of immunocompetent mice also coincided with production of antibodies to the human transgene. Significantly, 86% of the nude haemophilia mice developed tumours of myoblast origin. Thus, while this study revealed the feasibility of this gene therapy approach to treat severe haemophilia B, it also highlights the importance of using safer cell lines to prevent tumour development.

KW - C2C12 myoblast

KW - Factor IX

KW - Gene therapy

KW - Haemophilia B

KW - Microcapsules

UR - http://www.scopus.com/inward/record.url?scp=0035082874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035082874&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2516.2001.00492.x

DO - 10.1046/j.1365-2516.2001.00492.x

M3 - Article

VL - 7

SP - 207

EP - 214

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

IS - 2

ER -